Aethlon Medical, Inc. (AEMD) DCF Valuation

Aethlon Medical, Inc. (AEMD) Valoración de DCF

US | Healthcare | Medical - Devices | NASDAQ
Aethlon Medical, Inc. (AEMD) DCF Valuation
  • Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • Predeterminadas Para Un Uso Rápido Y Eficiente
  • No Se Necesita Experiencia; Fáciles De Seguir

Aethlon Medical, Inc. (AEMD) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Evalúe las perspectivas financieras de Aethlon Medical, Inc. (AEMD) como un experto! Esta calculadora DCF (AEMD) le proporciona datos financieros precipitados y la flexibilidad para personalizar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus predicciones.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue .7 .7 .3 .6 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 1.37 -55.37 95.21 -100 -14.7 -14.7 -14.7 -14.7 -14.7
EBITDA -6.3 -7.9 -10.3 -11.7 -11.8 .0 .0 .0 .0 .0
EBITDA, % -968.87 -1191.25 -3500.48 -2030.1 100 -60 -60 -60 -60 -60
Depreciation .0 .0 .1 .2 .4 .0 .0 .0 .0 .0
Depreciation, % 4.06 6.06 42.05 41.95 100 38.82 38.82 38.82 38.82 38.82
EBIT -6.3 -7.9 -10.4 -11.9 -12.2 .0 .0 .0 .0 .0
EBIT, % -972.92 -1197.31 -3542.53 -2072.05 100 -60 -60 -60 -60 -60
Total Cash 9.6 9.9 17.1 14.5 5.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .2 .1 .1 .0 .0
Account Receivables, % 31.8 22.62 43.5 0 100
Inventories -229.4 -340.7 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % -35278.22 -51697.44 0 0 100 -20 -20 -20 -20 -20
Accounts Payable .3 .3 .5 .4 .8 .0 .0 .0 .0 .0
Accounts Payable, % 43.84 51.23 169.96 75.38 100 74.09 74.09 74.09 74.09 74.09
Capital Expenditure -.2 -.1 -.3 -.9 -.3 .0 .0 .0 .0 .0
Capital Expenditure, % -23.33 -9.09 -118.71 -164.23 100 -46.48 -46.48 -46.48 -46.48 -46.48
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -6.3 -7.9 -10.4 -11.9 -12.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 223.0 103.6 -351.2 -12.5 -11.8 -.8 .0 .0 .0 .0
WACC, % 9.57 9.57 9.57 9.57 9.57 9.57 9.57 9.57 9.57 9.57
PV UFCF
SUM PV UFCF -.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -5
Equity Value 4
Diluted Shares Outstanding, MM 3
Equity Value Per Share 1.51

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real AEMD financials.
  • Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe how your inputs affect Aethlon Medical’s valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Customizable Financial Inputs: Adjust essential variables such as revenue projections, operating margins, and R&D expenditures.
  • Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and other financial metrics.
  • High-Precision Results: Incorporates Aethlon Medical’s actual financial data for accurate valuation assessments.
  • Effortless Scenario Testing: Evaluate various scenarios and analyze results with ease.
  • Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.

How It Works

  • Download: Obtain the pre-configured Excel file containing Aethlon Medical, Inc.'s (AEMD) financial data.
  • Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Generate various forecasts and evaluate results immediately.
  • Make Decisions: Leverage the valuation insights to shape your investment approach.

Why Choose This Calculator for Aethlon Medical, Inc. (AEMD)?

  • Accurate Data: Up-to-date Aethlon financials provide dependable valuation outcomes.
  • Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Built-in calculations save you the effort of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Simple design and detailed instructions ensure accessibility for all users.

Who Should Use Aethlon Medical, Inc. (AEMD)?

  • Investors: Gain insights into innovative medical technologies to make informed investment choices.
  • Healthcare Analysts: Streamline your analysis with comprehensive data on Aethlon's products and market potential.
  • Consultants: Easily modify presentations or reports to showcase Aethlon's strategic advantages to clients.
  • Medical Researchers: Enhance your understanding of cutting-edge therapies and their implications in the healthcare landscape.
  • Educators and Students: Utilize real-world case studies from Aethlon to enrich finance and medical curricula.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Aethlon Medical, Inc. (AEMD) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Aethlon Medical, Inc. (AEMD).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.